Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 16/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | CEL | P19835 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12676738 | 0.82 | HPGD (0.43) | HPGDGRM2 | |
| SCHEMBL12676736 | 0.81 | IDO1 (0.43) | HPGDNFE2L2 | |
| SCHEMBL2761782 | 0.74 | HPGD (0.42) | HPGD | |
| SCHEMBL1904148 | 0.65 | ALDH1A1 (0.36) | HPGD | |
| SCHEMBL2761641 | 0.65 | MAOA (0.56) | HPGDGRM2 | |
| SCHEMBL2761656 | 0.64 | PTGS2 (0.40) | HPGD | |
| SCHEMBL13243995 | 0.63 | TSHR (0.54) | HPGDNFE2L2 | |
| SCHEMBL30674516 | 0.63 | TSHR (0.54) | HPGDNFE2L2 | |
| SCHEMBL1907081 | 0.61 | IDO1 (0.67) | HPGDNFE2L2 | |
| SCHEMBL1642368 | 0.60 | MEN1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2493862-B1 | IMIDAZOLE DERIVATIVES AS IDO INHIBITORS | NEWLINK GENETICS CORP (US) | 2016-10-05 | — | — | EP | disclosed |
| EP-2493862-B1 | IMIDAZOLE DERIVATIVES AS IDO INHIBITORS | NEWLINK GENETICS CORP (US) | 2016-10-05 | — | — | EP | disclosed |
| US-8722720-B2 | Imidazole derivatives as IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722720-B2 | Imidazole derivatives as IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722720-B2 | Imidazole derivatives as IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-05-13 | — | — | US | disclosed |
| US-20120277217-A1 | Imidazole Derivatives as IDO Inhibitors | NEWLINK GENETICS CORPORATION (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277217-A1 | Imidazole Derivatives as IDO Inhibitors | NEWLINK GENETICS CORPORATION (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277217-A1 | Imidazole Derivatives as IDO Inhibitors | NEWLINK GENETICS CORPORATION (US) | 2012-11-01 | — | — | US | disclosed |
| WO-2011056652-A1 | IMIDAZOLE DERIVATIVES AS IDO INHIBITORS | NEWLINK GENETICS (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277217-A1 | Imidazole Derivatives as IDO Inhibitors | IDO1, IDO2, INMT | HPGD 129/4885GRM2 2290/4885NFE2L2 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.